PBAC's latest decision on Filgrastim: Recommended (2018). Considered for Chemotherapy-induced neutropenia, mobilisation of peripheral blood progenitor cells, bone marrow transplantation, autologous peripheral blood progenitor cell transplantation, severe congenital neutropenia, severe chronic neutropenia, and chronic cyclical neutropenia.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2010
Submissions
2
2010 → 2018
Eligible population
Patients requiring filgrastim for chemotherapy-induced neutropenia, mobilisation of peripheral blood progenitor cells, bone marrow transplantation, autologous peripheral blood progenitor cell transplantation, severe congenital neutropenia, severe chronic neutropenia, and chronic cyclical neutropenia.
Therapy area
Haematology
Line of therapy
Not applicable
Evidence base
Registry
Primary endpoint
Surrogate
Key trials
MONITOR-GCSF, VENICE, Blackwell et al (2017)
Economic model
Not modelled
ICER note
Not applicable — this is a minor submission for restriction level amendment and brand equivalence determination; no economic evaluation conducted.
Submission history
Nov 2010: Recommended with restriction · Restricted